← Leaderboards
Kenneth J. Pienta
Johns Hopkins University
$43,861,680
Attributed
$53,047,419
Total exposure
35
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $25.9M · FY2005–25$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$120,468,531 · 40
By mechanism
UL1$41,873,913 · 12
P50$32,585,847 · 6
UM1$15,688,154 · 4
U54$10,775,339 · 3
U01$8,437,641 · 2
P01$4,648,545 · 4
Top collaborators
- Scott Roberts16 shared
- Arul M Chinnaiyan8 shared
- Angelo Michael De Marzo7 shared
- Denis Wirtz7 shared
- David R Rowley6 shared
- Evan Todd Keller4 shared
- Scott J Roberts4 shared
- Yusuke Shiozawa4 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateMalignant NeoplasmsTumorCellsUniversitiesProgramsCessation Of LifeNeoplasm MetastasisNeoplastic CellBaseMolecularProstateTissuesMetastatic Neoplasm To The BoneCancer CellMichiganCancer PatientBone MarrowOrganUnited StatesGrantReportingGenomicsBiology
Grant awards (146)
Project 2: Dual Targeting of B7-H3 in mCRPC$377,386
P50 · FY2025 · CA · contact PI
Project 2: Dual Targeting of B7-H3 in mCRPC$366,800
P50 · FY2024 · CA · contact PI
Project 1: Polyploid giant cancer cells are central actuators of tumorigenesis, skeletal metastasis, and therapeutic resistance$135,264
P01 · FY2024 · CA · contact PI
Project 1: Polyploid giant cancer cells are central actuators of tumorigenesis, skeletal metastasis, and therapeutic resistance$142,381
P01 · FY2023 · CA · contact PI
Project 1: Polyploid giant cancer cells are central actuators of tumorigenesis, skeletal metastasis, and therapeutic resistance$139,606
P01 · FY2022 · CA · contact PI
Project 1: Polyploid giant cancer cells are central actuators of tumorigenesis, skeletal metastasis, and therapeutic resistance$142,293
P01 · FY2021 · CA · contact PI
Prostate Cancer Program - 07$55,386
P30 · FY2021 · CA · contact PI
The Johns Hopkins Physical Sciences Oncology Center$2,020,087
U54 · FY2020 · CA
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$648,412
U01 · FY2020 · CA · contact PI
Project 1: Polyploid giant cancer cells are central actuators of tumorigenesis, skeletal metastasis, and therapeutic resistance$171,063
P01 · FY2020 · CA · contact PI
Prostate Cancer Program - 07$55,386
P30 · FY2020 · CA · contact PI
The Johns Hopkins Physical Sciences Oncology Center$1,745,120
U54 · FY2019 · CA
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$1,232,006
U01 · FY2019 · CA · contact PI
Macrophages induce a tumor-promoting stable EMT in prostate cancer$413,728
P01 · FY2019 · CA · contact PI
The JAK2 V617F mutation within B cells and T cells leads to a pro-tumor microenvironment$73,786
U54 · FY2019 · CA
The Johns Hopkins Physical Sciences Oncology Center$64,052
U54 · FY2019 · CA
Prostate Cancer Program - 07$55,386
P30 · FY2019 · CA · contact PI
The Johns Hopkins Physical Sciences Oncology Center$1,921,408
U54 · FY2018 · CA
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$1,122,515
U01 · FY2018 · CA · contact PI
Macrophages induce a tumor-promoting stable EMT in prostate cancer$426,523
P01 · FY2018 · CA · contact PI
Studying the impact of hypoxia on sarcoma cell intravasation$66,034
U54 · FY2018 · CA
Prostate Cancer Program - 07$55,372
P30 · FY2018 · CA · contact PI
Prostate Cancer Program - 07$6,863
P30 · FY2018 · CA · contact PI
Prostate Cancer Program - 07$2,068
P30 · FY2018 · CA · contact PI
The Johns Hopkins Physical Sciences Oncology Center$2,118,358
U54 · FY2017 · CA
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$802,958
U01 · FY2017 · CA · contact PI
Macrophages induce a tumor-promoting stable EMT in prostate cancer$375,848
P01 · FY2017 · CA · contact PI
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$327,000
U01 · FY2017 · CA · contact PI
Prostate Cancer Program - 07$55,301
P30 · FY2017 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,980,271
UM1 · FY2016 · HG
Sequencing, Analysis, and Interpretation of Sequencing$1,269,021
UM1 · FY2016 · HG
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$810,157
U01 · FY2016 · CA · contact PI
Clinical Genomic Study$400,840
UM1 · FY2016 · HG · contact PI
Macrophages induce a tumor-promoting stable EMT in prostate cancer$384,035
P01 · FY2016 · CA · contact PI
Ethical and Psychosocial Implications$310,410
UM1 · FY2016 · HG
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,930,815
UM1 · FY2015 · HG
Sequencing, Analysis, and Interpretation of Sequencing$1,242,163
UM1 · FY2015 · HG
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry$809,998
U01 · FY2015 · CA · contact PI
Clinical Genomic Study$357,727
UM1 · FY2015 · HG · contact PI
Ethical and Psychosocial Implications$330,925
UM1 · FY2015 · HG
Macrophages induce a tumor-promoting stable EMT in prostate cancer$252,464
P01 · FY2015 · CA · contact PI
Human Sample Acquisition Core (HSAC)$187,484
U54 · FY2015 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,940,764
UM1 · FY2014 · HG
Sequencing, Analysis, and Interpretation of Sequencing$1,202,393
UM1 · FY2014 · HG
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$511,752
U01 · FY2014 · CA · contact PI
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche$495,498
U54 · FY2014 · CA
Clinical Genomic Study$394,551
UM1 · FY2014 · HG · contact PI
Ethical and Psychosocial Implications$343,820
UM1 · FY2014 · HG
Human Sample Acquisition Core (HSAC)$111,482
U54 · FY2014 · CA · contact PI
Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers$1,992,227
UM1 · FY2013 · HG
Sequencing, Analysis, and Interpretation of Sequencing$1,218,433
UM1 · FY2013 · HG
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$524,453
U01 · FY2013 · CA · contact PI
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche$487,171
U54 · FY2013 · CA
Clinical Genomic Study$421,677
UM1 · FY2013 · HG · contact PI
Ethical and Psychosocial Implications$352,117
UM1 · FY2013 · HG
Prostate Cancer Induces CCL2 Expression and Transforms the Bone Microenvi$213,604
P01 · FY2013 · CA · contact PI
Human Sample Acquisition Core (HSAC)$193,597
U54 · FY2013 · CA · contact PI
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche$612,460
U54 · FY2012 · CA
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$307,682
U01 · FY2012 · CA · contact PI
Administration Core$267,011
P50 · FY2012 · CA · contact PI
Prostate Cancer Induces CCL2 Expression and Transforms the Bone Microenvi$228,719
P01 · FY2012 · CA · contact PI
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$214,579
U01 · FY2012 · CA · contact PI
Human Sample Acquisition Core (HSAC)$137,802
U54 · FY2012 · CA · contact PI
SPORE in Prostate Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$552,256
U01 · FY2011 · CA · contact PI
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche$541,000
U54 · FY2011 · CA
Administration Core$254,873
P50 · FY2011 · CA · contact PI
Prostate Cancer Induces CCL2 Expression and Transforms the Bone Microenvi$230,241
P01 · FY2011 · CA · contact PI
Carryover from year -09 for Phase II Evaluation of EMD 12194$1
P50 · FY2011 · CA · contact PI
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1)$8,027,063
UL1 · FY2010 · RR · contact PI
SPORE in Prostate Cancer$2,300,000
P50 · FY2010 · CA · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$997,060
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$997,060
UL1 · FY2010 · RR · contact PI
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression$573,873
U01 · FY2010 · CA · contact PI
Administration Core$270,052
P50 · FY2010 · CA · contact PI
Prostate Cancer Induces CCL2 Expression and Transforms the Bone Microenvi$239,253
P01 · FY2010 · CA · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$99,706
UL1 · FY2010 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$99,706
UL1 · FY2010 · RR · contact PI
Annual Meeting for the Clinical Research Ethics Key Function Committee$25,000
R13 · FY2010 · RR · contact PI
Carryover from year -09 for Phase II Evaluation of EMD 12194$1
P50 · FY2010 · CA · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (UL1)$10,180,186
UL1 · FY2009 · RR · contact PI
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1)$8,269,365
UL1 · FY2009 · RR · contact PI
SPORE in Prostate Cancer$2,300,000
P50 · FY2009 · CA · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$1,008,449
UL1 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$705,894
UL1 · FY2009 · RR · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (TL1)$630,558
TL1 · FY2009 · RR · contact PI
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)$507,277
UL1 · FY2009 · RR · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (UL1)$507,277
UL1 · FY2009 · RR · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (KL2)$503,765
KL2 · FY2009 · RR · contact PI
The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule$374,197
U19 · FY2009 · CA · contact PI
Administration Core$270,391
P50 · FY2009 · CA · contact PI
Prostate Cancer Induces CCL2 Expression and Transforms the Bone Microenvi$233,843
P01 · FY2009 · CA · contact PI
SPORE in Prostate Cancer$163,548
P50 · FY2009 · CA · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$98,239
UL1 · FY2009 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$98,239
UL1 · FY2009 · RR · contact PI
Carryover from year -09 for Phase II Evaluation of EMD 12194$1
P50 · FY2009 · CA · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (UL1)$10,278,392
UL1 · FY2008 · RR · contact PI
SPORE in Prostate Cancer$2,300,000
P50 · FY2008 · CA · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (TL1)$634,705
TL1 · FY2008 · RR · contact PI
Michigan Institute for Clinical and Health Research (MICHR) (KL2)$404,650
KL2 · FY2008 · RR · contact PI
The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule$400,543
U19 · FY2008 · CA · contact PI
Administration Core$269,656
P50 · FY2008 · CA · contact PI
PAR1 in prostate cancer cell motility and invasion$250,766
P01 · FY2008 · CA · contact PI
Carryover from year -09 for Phase II Evaluation of EMD 12194$59,209
P50 · FY2008 · CA · contact PI
S.P.O.R.E. in Prostate Cancer$2,519,289
P50 · FY2007 · CA · contact PI
The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule$382,753
U19 · FY2007 · CA · contact PI
PAR1 in prostate cancer cell motility and invasion$250,074
P01 · FY2007 · CA · contact PI
S.P.O.R.E. in Prostate Cancer$2,355,770
P50 · FY2006 · CA · contact PI
Molecular Changes Associated with PCa bone metastases$331,504
R01 · FY2006 · CA · contact PI
The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule$257,087
U19 · FY2006 · CA · contact PI
PAR1 in prostate cancer cell motility and invasion$142,918
P01 · FY2006 · CA · contact PI
S.P.O.R.E. in Prostate Cancer$2,412,075
P50 · FY2005 · CA
Molecular Changes Associated with PCa bone metastases$339,482
R01 · FY2005 · CA
The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule$257,087
U19 · FY2005 · CA
PAR1 in prostate cancer cell motility and invasion$139,856
P01 · FY2005 · CA
S.P.O.R.E. in Prostate Cancer$2,286,693
P50 · FY2004 · CA
Molecular Changes Associated with PCa bone metastases$339,482
R01 · FY2004 · CA
Urology Research Training Grant$145,457
T32 · FY2004 · DK
PAR1 in prostate cancer cell motility and invasion$136,066
P01 · FY2004 · CA
S.P.O.R.E. in Prostate Cancer$2,300,000
P50 · FY2003 · CA
Molecular Changes Associated with PCa bone metastases$339,482
R01 · FY2003 · CA
UROLOGY RESEARCH TRAINING GRANT$187,481
T32 · FY2003 · DK
SPORE IN PROSTATE CANCER$1,250,001
P50 · FY2002 · CA
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2002 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2002 · CA
UROLOGY RESEARCH TRAINING GRANT$132,392
T32 · FY2002 · DK
PILOT--PROSTATE CANCER AND UROLOGICAL ONCOLOGY$0
P30 · FY2002 · CA
SPORE IN PROSTATE CANCER$2,940,900
P50 · FY2001 · CA
UROLOGY RESEARCH TRAINING GRANT$182,160
T32 · FY2001 · DK
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2001 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2001 · CA
PILOT--PROSTATE CANCER AND UROLOGICAL ONCOLOGY$0
P30 · FY2001 · CA
SPORE IN PROSTATE CANCER$2,564,919
P50 · FY2000 · CA
SPORE IN PROSTATE CANCER$346,638
P50 · FY2000 · CA
UROLOGY RESEARCH TRAINING GRANT$191,242
T32 · FY2000 · DK
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2000 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2000 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2000 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2000 · CA
INHIBITION OF HUMAN PROSTATE CANCER METASTASIS$165,355
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$165,355
P50 · FY2000 · CA
SPORE IN PROSTATE CANCER$136,785
P50 · FY2000 · CA
PROSTATE CANCER METASTASIS TO BONE$114,303
R21 · FY2000 · CA
SPORE IN PROSTATE CANCER$104,588
P50 · FY2000 · CA